U.S. healthcare insurance giant Centene Corporation experienced significant stock volatility on Friday following the release of its fourth-quarter 2025 earnings report and a mixed outlook for fiscal year 2026. The company’s shares declined despite beating earnings expectations, as investors weighed the complexities of its evolving business landscape across Medicaid, Marketplace, and prescription drug plan (PDP) segments.
Fourth Quarter Earnings Exceed Analyst Expectations
Centene Corporation delivered better-than-expected fourth-quarter results, reporting an adjusted loss of $1.19 per share. This performance surpassed the consensus analyst estimate of a $1.22 loss per share, demonstrating the company’s ability to manage costs during a challenging transition period. The quarter’s adjusted loss represents a significant shift from the prior year’s fourth quarter, when Centene posted earnings of 80 cents per share, reflecting the fundamental changes occurring within the healthcare insurance industry.
Revenue Growth Driven by Premium Increases
The healthcare insurer demonstrated robust top-line growth, with total sales surging from $40.81 billion to $49.73 billion year-over-year. This substantial 22% revenue increase exceeded Wall Street’s consensus estimate of $48.39 billion, highlighting Centene’s ability to expand its market presence despite operational headwinds.
Premium and Service Revenue Performance
Premium and service revenues specifically climbed 23% to reach $44.7 billion in the fourth quarter of 2025. This impressive growth was primarily fueled by several key factors including enhanced premium yield and expanding membership in the prescription drug plan business. Additionally, the company benefited from overall market expansion in its Marketplace business segment, along with rate increases and state-directed payments in the Medicaid division. However, these gains were partially offset by declining Medicaid enrollment across several states.
Health Benefits Ratio Shows Significant Increase
Centene’s health benefits ratio (HBR) rose to 94.3% in the fourth quarter, up substantially from 89.6% during the same period last year. This 470 basis point increase represents a critical metric for investors, as it indicates the percentage of premium revenues spent on medical care and quality improvement activities.
Factors Driving HBR Expansion
The HBR increase stemmed primarily from higher Marketplace morbidity in 2025, which resulted in elevated medical costs. Additionally, program changes in the prescription drug plan business resulting from the Inflation Reduction Act (IRA) contributed to the ratio expansion compared to the fourth quarter of 2024. Despite the overall increase, Centene’s Medicaid HBR actually improved by 40 basis points, driven by favorable rate and revenue increases, though partially offset by higher medical costs related to behavioral health and home health services.
Membership Trends Reflect Industry Challenges
Total membership across Centene’s comprehensive portfolio declined to 27.63 million members from 28.60 million a year ago. This net reduction of approximately 970,000 members was predominantly attributable to decreased Medicaid enrollment, which fell from 13.00 million to 12.52 million members. The Medicaid membership decline reflects ongoing eligibility redeterminations following the end of pandemic-era continuous enrollment provisions.
Commercial Segment Shows Strong Growth
Offsetting the Medicaid losses, Centene’s commercial membership segment demonstrated impressive expansion, jumping from 4.81 million to 5.99 million members year-over-year. This 24.5% growth in commercial enrollment underscores the company’s successful diversification strategy and its ability to compete effectively in the individual and group insurance markets.
Leadership Perspective on Recovery Efforts
Centene CEO Sarah London provided context for the company’s performance and strategic direction. “We are pleased to end a challenging year carrying positive momentum from the extensive and decisive actions taken in the back half of 2025 with the goal of restoring Marketplace profitability and stabilizing the trajectory of our Medicaid business,” London stated. Her comments reflect management’s focus on operational improvements and strategic repositioning to address the challenges that emerged throughout 2025.
